Psoriasis drug discovery: Methods for evaluation of potential drug candidates

Expert Opinion on Drug Discovery

Volumn 7, Issue 1, 2012, Pages 49-61

  Svensson, Lars ^a   Røpke, Mads A ^a   Norsgaard, Hanne ^b  

^a Department of Disease Pharmacology ^*  (Denmark)

^b LEO PHARMA A S   (Denmark)

Author keywords

Angiogenesis; Dermatology; Drug discovery; Epidermal hyperplasia; Experimental clinical studies; in vivo models; Inflammation; Pathogenesis; Psoriasis; Therapeutics

Indexed keywords

ANTIPSORIASIS AGENT;

DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; EXPERIMENTAL MODEL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALS; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84855378335     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.632629     Document Type: Review

References (119)

1. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011;127:1420-32
2. Elder JT, Bruce AT, Gudjonsson JE, et al. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010;130:1213-26
3. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339-50
4. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11 (Pubitemid 351543220)
5. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006;78:827-51
6. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008;128:1653-61 (Pubitemid 351847381)
7. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199-204
8. Feng BJ, Sun LD, Soltani-Arabshahi R, et al. Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet 2009;5:e1000606
9. de Cid R, Riveira-Munoz E, Zeeuwen PL, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009;41:211-15
10. Zhang XJ, Huang W, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 2009;41:205-10
11. Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One 2011;6:e17160
12. Mossner R, Reich K. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. Curr Probl Dermatol 2009;38:107-36
13. Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011;71:1733-53
14. Paul C, Gallini A, Maza A, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):2-11
15. van Lumig P, Driessen R, Berends M, et al. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol 2011;doi: 10.1111/j.1468-3083.2011.04044.x.
16. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011;222:363-74
17. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol 2011;391-414
18. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011;32:25-34
19. Chang T, Sun L, Wang Y, et al. Inhibition of keratin 17 expression with antisense and RNAi strategies: exploring novel therapy for psoriasis. Exp Dermatol 2011;20:555-60
20. Jakobsen M, Stenderup K, Rosada C, et al. Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. Mol Ther 2009;17:1743-53
21. Swanson R, Beasley JR. Pathway-specific, species, and sub-type counterscreening for better GPCR hits in high throughput screening. Curr Pharm Biotechnol 2010;11:757-63
22. Pastore S, Lulli D, Potapovich AI, et al. Differential modulation of stress-inflammation responses by plant polyphenols in cultured normal human keratinocytes and immortalized HaCaT cells. J Dermatol Sci 2011;63:104-14
23. Ridd K, Dhir S, Smith AG, et al. Defective TPA signalling compromises HaCat cells as a human in vitro skin carcinogenesis model. Toxicol In Vitro 2010;24:910-15
24. Lewis DA, Hengeltraub SF, Gao FC, et al. Aberrant NF-kappaB activity in HaCaT cells alters their response to UVB signaling. J Invest Dermatol 2006;126:1885-92 (Pubitemid 44086524)
25. Ratnam AV, Bikle DD, Su MJ, et al. Squamous carcinoma cell lines fail to respond to 1,25-Dihydroxyvitamin D despite normal levels of the vitamin D receptor. J Invest Dermatol 1996;106:522-5 (Pubitemid 26117587)
26. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006;7:243
27. Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2007;2:e610
28. Zibert JR, Lovendorf MB, Litman T, et al. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010;58:177-85
29. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-55
30. Burgler S, Ouaked N, Bassin C, et al. Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009;123:588-95.595
31. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43
32. Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005;11:43-9 (Pubitemid 40215836)
33. Swindell WR, Johnston A, Carbajal S, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One 2011;6:e18266
34. Nakajima K, Kanda T, Takaishi M, et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011;186:4481-9
35. van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182:5836-45
36. Patel U, Mark NM, Machler BC, et al. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol 2011;164:670-2
37. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87 (Pubitemid 44833335)
38. Lindroos J, Svensson L, Norsgaard H, et al. IL-23-mediated epidermal hyperplasia is dependent on IL-6. J Invest Dermatol 2011;131:1110-18
39. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
40. Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009;90:232-48
41. Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008;173:265-77 (Pubitemid 351947973)
42. Abe R, Yamagishi S, Fujita Y, et al. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. J Dermatol Sci 2010;57:183-91
43. Folkman J. Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol 1972;59:40-3
44. Nacev B, Low WK, Huang Z, et al. A calcineurin-independent mechanism of angiogenesis inhibition by a non-immunosuppressive Cyclosporin A analog. J Pharmacol Exp Ther 2011;338:466-75
45. Rossi B, Schinzari G, Maccauro G, et al. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord 2010;11:34
46. Sethi G, Sung B, Kunnumakkara AB, et al. Targeting TNF for treatment of cancer and autoimmunity. Adv Exp Med Biol 2009;647:37-51
47. Micali G, Lacarrubba F, Musumeci ML, et al. Cutaneous vascular patterns in psoriasis. Int J Dermatol 2010;49:249-56
48. Garcia-Caballero M, Mari-Beffa M, Medina MA, et al. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect? J Invest Dermatol 2011;131:1347-55
49. Narayanan S, Callis-Duffin K, Batten J, et al. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci 2010;339:580-1
50. Akman A, Yilmaz E, Mutlu H, et al. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 2009;34:e202-4
51. Sauder DN, Dekoven J, Champagne P, et al. Neovastat (AE-941), an inhibitor of angiogenesis: randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002;47:535-41
52. Voskas D, Jones N, Van SP, et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 2005;166:843-55 (Pubitemid 40315641)
53. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998;111:1-6 (Pubitemid 28309201)
54. Kunstfeld R, Hirakawa S, Hong YK, et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004;104:1048-57 (Pubitemid 39038025)
55. Hvid H, Teige I, Kvist PH, et al. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol 2008;20:1097-106
56. Teige I, Hvid H, Svensson L, et al. Regulatory T cells control VEGF-dependent skin inflammation. J Invest Dermatol 2009;129:1437-45
57. Takahashi H, Ibe M, Kinouchi M, et al. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003;31:21-8 (Pubitemid 36286955)
58. Bernard FX, Pedretti N, Rosdy M, et al. Comparison of gene expression profiles in human keratinocyte mono-layer cultures, reconstituted epidermis and normal human skin; transcriptional effects of retinoid treatments in reconstituted human epidermis. Exp Dermatol 2002;11:59-74 (Pubitemid 36934625)
59. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131:677-87
60. Boniface K, Bernard FX, Garcia M, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005;174:3695-702 (Pubitemid 40354080)
61. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40 (Pubitemid 46233421)
62. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1092-102
63. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009;87:523-36
64. Gudjonsson JE, Ding J, Johnston A, et al. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010;130:1829-40
65. Guilloteau K, Paris I, Pedretti N, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, Oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J Immunol 2010;184:5263-70
66. Tjabringa G, Bergers M, van RD, et al. Development and validation of human psoriatic skin equivalents. Am J Pathol 2008;173:815-23
67. Jean J, Lapointe M, Soucy J, et al. Development of an in vitro psoriatic skin model by tissue engineering. J Dermatol Sci 2009;53:19-25
68. Barker CL, McHale MT, Gillies AK, et al. The development and characterization of an in vitro model of psoriasis. J Invest Dermatol 2004;123:892-901 (Pubitemid 39391935)
69. Konstantinova NV, Duong DM, Remenyik E, et al. Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol 1996;107:615-21 (Pubitemid 26338589)
70. Jean J, Soucy J, Pouliot R. Effects of retinoic acid on keratinocyte proliferation and differentiation in a psoriatic skin model. Tissue Eng Part A 2011;17:1859-68
71. Schon MP. Animal models of psoriasis: a critical appraisal. Exp Dermatol 2008;17:703-12 (Pubitemid 352044366)
72. Gudjonsson JE, Johnston A, Dyson M, et al. Mouse models of psoriasis. J Invest Dermatol 2007;127:1292-308 (Pubitemid 46763003)
73. Han G, Williams CA, Salter K, et al. A role for TGFbeta signaling in the pathogenesis of psoriasis. J Invest Dermatol 2010;130:371-7
74. Michaelis K, Wallbrecht K, Kerstan A, et al. Modulating T cell functions does not alleviate chronic inflammatory skin lesions in K5.TGF beta 1 transgenic mice. Exp Dermatol 2010;19:406-15
75. Carroll JM, Romero MR, Watt FM. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 1995;83:957-68 (Pubitemid 26006537)
76. Teige I, Backlund A, Svensson L, et al. Induced keratinocyte hyper-proliferation in alpha2beta1 integrin transgenic mice results in systemic immune cell activation. Int Immunopharmacol 2010;10:107-14
77. Koegel H, von TL, Schafer M, et al. Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice. J Clin Invest 2009;119:899-910
78. Romanowska M, Reilly L, Palmer CN, et al. Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS ONE 2010;5:e9701
79. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-8 (Pubitemid 38263654)
80. Annunziato F, Romagnani S. Do studies in humans better depict Th17 cells? Blood 2009;114:2213-19
81. Kvist PH, Svensson L, Hagberg O, et al. Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model. J Transl Med 2009;7:107
82. Sugai J, Iizuka M, Kawakubo Y, et al. Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci 1998;17:85-92 (Pubitemid 28294258)
83. Stenderup K, Rosada C, Dam TN, et al. Resolution of psoriasis by a leukocyte-targeting bacterial protein in a humanized mouse model. J Invest Dermatol 2011;131:2033-9
84. Stenderup K, Rosada C, Alifrangis L, et al. Statistical evaluation and experimental design of a psoriasis xenograft transplantation model treated with cyclosporin A. Exp Dermatol 2011;20:441-4
85. Bak RO, Stenderup K, Rosada C, et al. Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. BMC Dermatol 2011;11:5
86. Stenderup K, Rosada C, Worsaae A, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009;160:284-96
87. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87 (Pubitemid 26359206)
88. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999;155:145-58 (Pubitemid 29318713)
89. Boyman O, Hefti HP, Conrad C, et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004;199:731-6 (Pubitemid 38316440)
90. Conrad C, Boyman O, Tonel G, et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007;13:836-42 (Pubitemid 47038192)
91. Dinh PH, Corazza F, Mestdagh K, et al. Validation of the cantharidin-induced skin blister as an in vivo model of inflammation. Br J Clin Pharmacol 2011;doi: 10.1111/j.1365-2125.2011.04020.x
92. Dumas KJ, Scholtz JR. The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol 1972;52:43-8
93. Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6 (Pubitemid 29010535)
94. Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141:103-7 (Pubitemid 29333700)
95. Rappersberger K, Meingassner JG, Fialla R, et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996;106:701-10 (Pubitemid 26120581)
96. Bangha E, Elsner P. Evaluation of topical antipsoriatic treatment by chromametry, visiometry and 20-MHz ultrasound in the psoriasis plaque test. Skin Pharmacol 1996;9:298-306
97. Buder K, Knuschke P, Wozel G. Evaluation of methylprednisolone aceponate, tacrolimus and combination thereof in the psoriasis plaque test using sum score, 20-MHz-ultrasonography and optical coherence tomography. Int J Clin Pharmacol Ther 2010;48:814-20
98. Benson NR, Papenfuss J, Wong R, et al. An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting. J Invest Dermatol 2006;126:2234-41 (Pubitemid 44413170)
99. Macdonald N, Cumberbatch M, Singh M, et al. Proteomic analysis of suction blister fluid isolated from human skin. Clin Exp Dermatol 2006;31:445-8
100. Salgo R, Thaci D, Boehncke S, et al. Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. Exp Dermatol 2011;20:130-3
101. Mrowietz U, Wustlich S, Hoexter G, et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003;83:351-3 (Pubitemid 37281542)
102. Parmar H. The application of advanced emerging technologies to novel biomarker discovery, target validation and earlier clinical Proof of Principle in Pharma R & D. Inflamm Res 2005(Suppl 2):S92-3
103. ICH. ICH M3(R2)-Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; 2009
104. Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010;49:1399-405
105. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011;20:81-7
106. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94
107. Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001;1:272-87 (Pubitemid 33756652)
108. Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003;13:69-78 (Pubitemid 37129170)
109. Gudjonsson JE, Ding J, Li X, et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 2009;129:2795-804
110. Guttman-Yassky E, Suarez-Farinas M, Chiricozzi A, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009;124:1235-44
111. Racz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011;131:1547-58
112. Kim BE, Howell MD, Guttman E, et al. TNF-alpha downregulates Filaggrin and Loricrin through c-Jun N-terminal Kinase: role for TNF-alpha antagonists to improve skin barrier. J Invest Dermatol 2011;131:1272-9
113. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124:1022-10
114. Johansen C, Vinter H, Soegaard-Madsen L, et al. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFalpha therapy. Br J Dermatol 2010;163:1194-204
115. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009;136:26-36
116. Suarez-Farinas M, Shah KR, Haider AS, et al. Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. BMC Dermatol 2010;10:1
117. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, et al. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 2011;131:391-400
118. Boehncke WH, Boehncke S, Tobin AM, et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-7
119. Norsgaard H, Svensson L, Hagedorn PH, et al. Translating clinical activity and gene expression signatures of etanercept and cyclosporine A to the psoriasis xenograft SCID mouse model. Br J Dermatol 2011; in press